Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection

References

1. 1.↵
   2. Trapp BD,
   3. Peterson J,
   4. Ransohoff RM, et al

   . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85 doi:10.1056/NEJM199801293380502 pmid:9445407

   CrossRefPubMedWeb of Science
2. 2.↵
   2. McFarland HF,
   3. Martin R

   . Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8:913–19 doi:10.1038/ni1507 pmid:17712344

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Lublin FD,
   3. Reingold SC

   . Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11 doi:10.1212/WNL.46.4.907 pmid:8780061

   Abstract/FREE Full Text
4. 4.↵
   2. Polman CH,
   3. Reingold SC,
   4. Banwell B, et al

   . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Vellinga MM,
   3. Oude Engberink RD,
   4. Seewann A, et al

   . Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008;131:800–07 doi:10.1093/brain/awn009 pmid:18245785

   Abstract/FREE Full Text
6. 6.↵
   2. Ladewig G,
   3. Jestaedt L,
   4. Misselwitz B, et al

   . Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study. Exp Neurol 2009;220:207–11 doi:10.1016/j.expneurol.2009.08.027 pmid:19733560

   CrossRefPubMed
7. 7.↵
   2. Kanda T,
   3. Osawa M,
   4. Oba H, et al

   . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

   CrossRefPubMed
8. 8.↵
   2. Radbruch A,
   3. Weberling LD,
   4. Kieslich PJ, et al

   . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

   CrossRefPubMed
9. 9.↵
   2. Roccatagliata L,
   3. Vuolo L,
   4. Bonzano L, et al

   . Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009;251:503–10 doi:10.1148/radiol.2511081269 pmid:19401576

   CrossRefPubMed
10. 10.↵
    2. Shinohara RT,
    3. Goldsmith J,
    4. Mateen FJ, et al

    . Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents. AJNR Am J Neuroradiol 2012;33:1586–90 doi:10.3174/ajnr.A2997 pmid:22442041

    Abstract/FREE Full Text
11. 11.↵
    2. Treabă CA,
    3. Bălaşa R,
    4. Podeanu DM, et al

    . Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? Diagn Interv Radiol 2014;20:178–84 doi:10.5152/dir.2013.13313 pmid:24378990

    CrossRefPubMed
12. 12.↵
    2. Blystad I,
    3. Håkansson I,
    4. Tisell A, et al

    . Quantitative MRI for analysis of active multiple sclerosis lesions without gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016;37:94–100 doi:10.3174/ajnr.A4501 pmid:26471751

    Abstract/FREE Full Text
13. 13.↵
    2. Lo CP,
    3. Kao HW,
    4. Chen SY, et al

    . Comparison of diffusion-weighted imaging and contrast-enhanced T1-weighted imaging on a single baseline MRI for demonstrating dissemination in time in multiple sclerosis. BMC Neurol 2014;14:100 doi:10.1186/1471-2377-14-100 pmid:24885357

    CrossRefPubMed
14. 14.↵
    2. Lee SC,
    3. Moore GR,
    4. Golenwsky G, et al

    . Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurol 1990;49:122–36 doi:10.1097/00005072-199003000-00005 pmid:2307980

    CrossRefPubMed
15. 15.↵
    2. Brück W,
    3. Porada P,
    4. Poser S, et al

    . Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788–96 doi:10.1002/ana.410380514 pmid:7486871

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Mehta V,
    3. Pei W,
    4. Yang G, et al

    . Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013;8:e57573 doi:10.1371/journal.pone.0057573 pmid:23516409

    CrossRefPubMed
17. 17.↵
    2. Kutzelnigg A,
    3. Lassmann H

    . Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 2014;122:15–58 doi:10.1016/B978-0-444-52001-2.00002-9 pmid:24507512

    CrossRefPubMed
18. 18.↵
    2. Cairo G,
    3. Recalcati S,
    4. Mantovani A, et al

    . Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol 2011;32:241–47 doi:10.1016/j.it.2011.03.007 pmid:21514223

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Chen W,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–92 doi:10.1148/radiol.13130353 pmid:24475808

    CrossRefPubMed
20. 20.↵
    2. Wiggermann V,
    3. Hernández Torres E,
    4. Vavasour IM, et al

    . Magnetic resonance frequency shifts during acute MS lesion formation. Neurology 2013;81:211–18 doi:10.1212/WNL.0b013e31829bfd63 pmid:23761621

    Abstract/FREE Full Text
21. 21.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM). J Magn Reson Imaging 2016 Jan 22. [Epub ahead of print] doi:10.1002/jmri.25144 pmid:26800367

    CrossRefPubMed
22. 22.↵
    2. de Rochefort L,
    3. Liu T,
    4. Kressler B, et al

    . Quantitative susceptibility map reconstruction from MR phase data using Bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194–206 doi:10.1002/mrm.22187 pmid:19953507

    CrossRefPubMed
23. 23.↵
    2. Wang Y,
    3. Liu T

    . Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015;73:82–101 doi:10.1002/mrm.25358 pmid:25044035

    CrossRefPubMed
24. 24.↵
    2. Liu J,
    3. Liu T,
    4. de Rochefort L, et al

    . Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560–68 doi:10.1016/j.neuroimage.2011.08.082 pmid:21925276

    CrossRefPubMed
25. 25.↵
    2. Jenkinson M,
    3. Bannister P,
    4. Brady M, et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 doi:10.1006/nimg.2002.1132 pmid:12377157

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Gaitán MI,
    3. Shea CD,
    4. Evangelou IE, et al

    . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22–29 doi:10.1002/ana.22472 pmid:21710622

    CrossRefPubMed
27. 27.↵
    2. Wisnieff C,
    3. Ramanan S,
    4. Olesik J, et al

    . Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: interpreting positive susceptibility and the presence of iron. Magn Reson Med 2015;74:564–70 doi:10.1002/mrm.25420 pmid:25137340

    CrossRefPubMed
28. 28.↵
    2. Haacke EM,
    3. Makki M,
    4. Ge Y, et al

    . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537–44 doi:10.1002/jmri.21676 pmid:19243035

    CrossRefPubMed
29. 29.↵
    2. Khalil M,
    3. Enzinger C,
    4. Langkammer C, et al

    . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1048–54 doi:10.1177/1352458509106609 pmid:19556316

    Abstract/FREE Full Text
30. 30.↵
    2. Ropele S,
    3. de Graaf W,
    4. Khalil M, et al

    . MRI assessment of iron deposition in multiple sclerosis. J Magn Reson Imaging 2011;34:13–21 doi:10.1002/jmri.22590 pmid:21698703

    CrossRefPubMed
31. 31.↵
    2. Khalil M,
    3. Langkammer C,
    4. Ropele S, et al

    . Determinants of brain iron in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011;77:1691–97 doi:10.1212/WNL.0b013e318236ef0e pmid:21975210

    Abstract/FREE Full Text
32. 32.↵
    2. Hagemeier J,
    3. Heininen-Brown M,
    4. Poloni GU, et al

    . Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging 2012;36:73–83 doi:10.1002/jmri.23603 pmid:22407571

    CrossRefPubMed
33. 33.↵
    2. Paling D,
    3. Tozer D,
    4. Wheeler-Kingshott C, et al

    . Reduced R2′ in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content. J Neurol Neurosurg Psychiatry 2012;83:785–92 doi:10.1136/jnnp-2012-302541 pmid:22626944

    Abstract/FREE Full Text
34. 34.↵
    2. Bagnato F,
    3. Hametner S,
    4. Welch EB

    . Visualizing iron in multiple sclerosis. Magn Reson Imaging 2013;31:376–84 doi:10.1016/j.mri.2012.11.011 pmid:23347601

    CrossRefPubMed
35. 35.↵
    2. Bian W,
    3. Harter K,
    4. Hammond-Rosenbluth KE, et al

    . A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler 2013;19:69–75 doi:10.1177/1352458512447870 pmid:22641301

    Abstract/FREE Full Text
36. 36.↵
    2. Absinta M,
    3. Sati P,
    4. Gaitan MI, et al

    . Seven-Tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013;74:669–78 doi:10.1002/ana.23959 pmid:23813441

    CrossRefPubMed
37. 37.↵
    2. Cotton F,
    3. Weiner HL,
    4. Jolesz FA, et al

    . MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46 doi:10.1212/01.WNL.0000046587.83503.1E pmid:12601106

    Abstract/FREE Full Text
38. 38.↵
    2. Guttmann CR,
    3. Ahn SS,
    4. Hsu L, et al

    . The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995;16:1481–91 pmid:7484637

    Abstract